CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in a Phase 3 trial for the treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). Additional indications in Muscle Invasive Bladder Cancer (MIBC) and other solid tumors are being pursued with CG0070 in combination with immune checkpoint modulators. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):